Poplar Therapeutics

Poplar Therapeutics

Poplar Therapeutics

Developing a new class of anti-IgE therapy for multiple atopic conditions.

2021Active15Boston, USA

About

Poplar Therapeutics is a biotechnology company focused on developing novel therapies for atopic conditions. Their lead program, PHB-050, is a new class of anti-IgE therapy designed to address a range of allergic diseases.

Signals agent

Reach companies that have budget right now

Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.

  • Just raised a roundFresh budget, the week it lands
  • Hiring sales and marketingGo-to-market roles mean money to spend
  • Hiring fastA jump in open roles across the company
  • In the newsLaunches and announcements worth a message
  • The decision makerWho to contact, with a message you can edit

Is your startup an alternative to Poplar Therapeutics?

People comparing tools land here. Get listed beside these.

All funding rounds

Key facts

Website
poplartx.com
Headquarters
Boston, Massachusetts, USA
Founded
2021
Founder
Tony Yao
Employees
15
Total funding
$50M (Series A)
Business model
B2B

Funding rounds

Funding rounds raised by Poplar Therapeutics
DateRoundAmountLead investors
7 Jan 2026Series A$50MSR One

Tech stack

Detected on poplartx.com, last scanned 30 Oct 2026.

Frontend
jQuery
Analytics
Google Analytics 4
SEO
Yoast SEO
CMS / Builders
WordPress
CDN
Cloudflare
Email provider
Microsoft 365

Benchmarking

See how your site ranks against 16,849 startups

Poplar Therapeutics sits in the 2nd percentile for Domain Rating. Check where yours lands, free.

Check your Domain Rating

Poplar Therapeutics has a Domain Rating of 1, the 2nd percentile of 16,849 startups we track.

Scores

Measured, not editorial

1

Measured by AhrefsAhrefs DR

Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.

Bottom 25%

Check yours
40

Measured by StartupHub.aiAgent Readiness

How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.

Below median

Scan yours
64

Measured by Google PageSpeedSite Speed

Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.

Above median

PageSpeed
58

Measured by StartupHub.aiData Trust

Whether this company is a safe place to put your data: security posture, privacy signals, and reputation evidence we could verify.

Below median

Measured by StartupHub.aiSecurity

What this company’s API or MCP server gives an anonymous stranger: transport, whether anything answers without credentials, CORS, response headers and, when an MCP server replies, which of its tools can be called with no key. Scanned live, on request, because a security verdict months old is worse than none.

Click to scan

Agent Readiness

Can AI agents use your site?

Poplar Therapeutics scores 40. Check yours free in a few seconds, or let Max Agent rerun it daily.

Run it daily with Max Agent
Median 41Across 23,755 scanned sites

AI visibility

Get read by ChatGPT, Claude and Perplexity

List your startup, then track where you show up in AI answers.

AI reads of this profile

Last 14 days, from server logs

Get notified when Poplar Therapeutics changes

Used Poplar Therapeutics? Write a review and get $5 in credits

Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:

  • Email finder
  • Market Map Maker
  • Agent Readiness scans
  • Deep intel
  • Tech stack scans

Frequently asked

Is Poplar Therapeutics growing?

Yes, fast. Our data shows it raised $50M in a Series A in January 2026.

Who owns Poplar Therapeutics?

Poplar Therapeutics is privately held, owned by its founders and investors. Investors on record include SR One. Exact stakes are not public.

Are there companies like Poplar Therapeutics?

Yes. We list 7 companies like Poplar Therapeutics, including Novartis (Xolair), Moderna and Epicrispr Biotechnologies.

Is Poplar Therapeutics trustworthy and reputable?

StartupHub's Data Trust & Reputation score for Poplar Therapeutics is 58 out of 100, a use-caution rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.

How much funding has Poplar Therapeutics raised?

Poplar Therapeutics has raised a total of $50M in funding. The most recent round on record is Series A.

How many employees does Poplar Therapeutics have?

Poplar Therapeutics has approximately 15 people on record.

SEC filings, insider activity, nonprofit links and pay benchmarks for Poplar Therapeutics:

Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules

Categories

Need more than this profile? Deep intel researches any company website: team, funding, customers and tech.

Max Agent

Let Max Agent watch Poplar Therapeutics and its market for you

New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.

Free week

Starter listings, once

AI answers checked

Daily for 7 days

  • ChatGPT
  • Perplexity

Max Agent

$79 a month, or $9.99 with our badge on your site

AI answers checked

Every week

  • ChatGPT
  • Claude
  • Perplexity
  • Gemini